Ryan K. Shields

TL;DR: Among patients with acute stroke who had last been known to be well 6 to 24 hours earlier and who had a mismatch between clinical deficit and infarct, outcomes for disability at 90 days were better with thrombectomy plus standard care than with standard care alone.

TL;DR: The development of resistance-conferring blaKPC-3 mutations in K. pneumoniae within 10 to 19 days of ceftazidime-avibactam exposure is troubling, but clinical impact may be ameliorated if carbapenem susceptibility is restored in certain isolates.

TL;DR: Thirty-seven carbapenem-resistant Enterobacteriaceae-infected patients treated with ceftazidime-avibactam showed clinical success and survival rates and resistance was detected in 30% (3/10) of microbiologic failures.

TL;DR: There are no data comparing outcomes of patients treated with ceftazidime-avibactam versus comparators for carbapenem-resistant Enterobacteriaceae infections and across treatment groups, there were no differences in underlying diseases, severity of illness, source of bacteremia, or strain characteristics.

TL;DR: Colistin-resistant A. baumannii occurred almost exclusively among patients who had received CMS for treatment of carbapenem-resistant, colist in-susceptible, and -resistant isolates, suggesting evolution of resistance during CMS therapy.